at Benzinga.com (Jan 15, 2015)
Eli Lilly (LLY), which is suffering from a massive patent cliff and faces another one in 2017, could keep marketing exclusivity for its blockbuster Alimta lung cancer drug until 2022 rather than 2016 if it wins a case over a "method-of-use" patent on the way the multibillion dollar selling treatment is administered. Such IP is usually not upheld, although some experts believe that the Alimta case is different. Generic firms such as Teva (TEVA) argue otherwise.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs